OraSure Technologies to Host Media Briefing Following Blood Products Advisory Committee Meeting of the FDA; March 10th Committee Meeting to Address Proposed Studies to Support Approval of Over-the-Counter HIV Test Kits.

OraSure Technologies, Inc. (NASDAQ:OSUR):

WHAT:       OraSure Technologies, Inc. (NASDAQ:OSUR) CEO and President
            Douglas Michels will host an on-site media briefing
            following the Blood Products Advisory Committee (BPAC)
            meeting on March 10, 2006, to address the outcomes and
            next steps resulting from the BPAC discussion, as well as
            the potential for an OTC rapid HIV test from OraSure. The
            Company will be offering public comment at the BPAC
            meeting.  The media briefing will include an open Q&A
            session for media, who may also participate via
            teleconference.

            OraSure is the manufacturer of OraQuick(R) ADVANCE(TM),
            the first and only U.S. Food and Drug Administration
            approved and CLIA (Clinical Laboratory Improvements
            Amendments Act of 1988) waived rapid point-of-care test
            that can detect antibodies to both HIV-1 and HIV-2 in 20
            minutes, using oral fluid, finger-stick or venipuncture
            whole blood or plasma specimens.

            The BPAC meeting materials can be found at:
            http://www.fda.gov/ohrms/dockets/ac/cber06.html

            ** CONFERENCE CALL LINE AVAILABLE FOR MEDIA NOT ATTENDING
            BPAC MEETING **

WHEN:       March 10, 2006
            BPAC Meeting: OTC segment scheduled for 8:30 AM - 12 PM
            Media Briefing: 1 - 1:30 PM

WHERE:      Hilton Hotel, 620 Perry Parkway, Gaithersburg, MD, 20877
            BPAC Meeting: Grand Ballroom, Lobby level
            Media Briefing: Bethesda Room, Lobby level

DIAL-IN:    Please contact Jennifer Moritz at 917-748-4006 or Erika
            Freed at 917-359-7974 to obtain dial-in information.